A retrospective comparison of care in an ED versus a specialized sickle cell clinic finds ED analgesia to be stingy.
Patients with sickle cell anemia often have very high opioid tolerances, and when they present with the pain of vaso-occlusive crisis, their opioid requirements can be intimidating. Investigators retrospectively compared pain severity and opioid administration among adults receiving care in a single center's emergency department (ED) versus an affiliated specialized sickle cell anemia clinic.
The study included a total of 217 visits to the ED, clinic, or both by 148 adult patients over 2 years. Pain was significantly worse at visits to the ED, both on arrival (mean scores of 8.7 vs. 8.0 on a 10-point verbal scale) and at discharge (6.4 vs. 4.5). However, opioid doses were significantly lower in the ED, whether measured as intravenous morphin…
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals